Related Experiment Video

Updated: May 14, 2026

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer

Michael J Wagner1, Robert G Maki

  • 1Department of Medicine, Mount Sinai Medical Center New York, NY, USA.

Frontiers in Oncology
|February 6, 2013
PubMed

Insights

Insulin-like growth factor (IGF) signaling inhibitors show promise for pediatric cancers, but resistance limits effectiveness. Research explores overcoming resistance in Ewing sarcoma and rhabdomyosarcoma for better treatment outcomes.

Area of Science:

  • Pediatric Oncology
  • Molecular Targeted Therapy
  • Cancer Signaling Pathways

Background:

  • Insulin-like growth factor (IGF) signaling modulators, particularly IGF-1R antagonists, have shown preclinical promise for pediatric and adolescent cancers, especially sarcomas.
  • Despite early promise, clinical trials of IGF-1R inhibitors as single agents have yielded disappointing results due to tumor resistance.
  • Resistance mechanisms to IGF-1R inhibitors are increasingly understood, particularly in Ewing sarcoma and alveolar rhabdomyosarcoma.

Purpose of the Study:

  • To review the current understanding of IGF-1R inhibitors in pediatric cancers.
  • To explore the known mechanisms of tumor resistance to IGF-1R inhibitors.
  • To discuss potential treatment strategies aimed at overcoming resistance and highlight ongoing clinical trials.

Main Methods:

  • Literature review of preclinical and clinical data on IGF-1R inhibitors in pediatric cancers.
  • Analysis of established and emerging mechanisms of resistance to IGF-1R targeted therapy.
  • Summary of current clinical trial designs investigating IGF-1R inhibitors in pediatric malignancies.

Main Results:

  • Preclinical data strongly support the potential of IGF-1R inhibitors, but clinical efficacy as monotherapy has been limited.
  • Specific resistance pathways have been identified in key pediatric sarcomas like Ewing sarcoma and alveolar rhabdomyosarcoma.
  • Ongoing clinical studies are exploring combination therapies and novel treatment schemas to enhance efficacy.

Conclusions:

  • IGF-1R inhibitors remain a relevant therapeutic target for pediatric cancers, necessitating strategies to overcome resistance.
  • Understanding tumor-specific resistance mechanisms is crucial for designing effective combination therapies.
  • Further clinical investigation is required to establish the role of IGF-1R inhibitors in improving outcomes for children and adolescents with cancer.
Keywords:
IGF-1Rinsulin-like growth factor pathwaypediatric cancerresistance mechanismssarcoma

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.